
Novo Nordisk Eyes M&A to Diversify Beyond GLP-1 Amid Weight-Loss Push
Novo Nordisk signaled it may pursue acquisitions to close gaps against rivals in the crowded weight‑loss market, as investors reacted skeptically to a Capital Markets Day plan. CEO Mike Doustdar said the firm aims to diversify beyond diabetes and obesity into adjacent areas and could strike deals outside its core as Wegovy’s exclusivity wanes, with a long‑range plan to launch five multi‑blockbuster drugs by 2030 and target more than 150 billion Danish kroner in sales by 2035; the stock has faced pressure amid the broader competitive landscape, including Lilly’s dominance in GLP-1 therapies.












